Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of gemcitabine + cisplatin, radiotherapy, and slulimumab for first-line intrahepatic cholangiocarcinoma
ChiCTR2400085391Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: progression-free survival. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2400085391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085391.